Phase IIb results from the TYDAL-TIMI 78 trial, presented at the American Heart Association (AHA) Scientific Sessions 2026, showed that Marea Therapeutics’ MAR001 achieved substantial reductions in triglycerides and remnant cholesterol in patients with dyslipidemia. The findings highlight the potential of angiopoietin-like protein 4 (ANGPTL4) inhibition as a new approach to managing lipid abnormalities and addressing residual cardiovascular risk, says GlobalData, a leading intelligence and productivity platform.

Elevated triglyceride (TG) and remnant cholesterol levels are associated with increased cardiovascular risk, while severe hypertriglyceridemia also increases the risk of acute pancreatitis. Despite existing treatments, some patients struggle to achieve adequate lipid control. ANGPTL4 inhibits lipoprotein lipase, an enzyme responsible for breaking down TGs, making it a promising therapeutic target. MAR001 is a potential first-in-class monoclonal antibody designed to inhibit ANGPTL4 and enhance TG clearance.

Maria Alexandrovich, Pharma Analyst at GlobalData, comments: “MAR001’s early and sustained TG reductions, alongside its effects on remnant cholesterol, could strengthen Marea Therapeutics’ position in the increasingly competitive TG-lowering market. Its novel mechanism offers potential differentiation from emerging treatments, including apolipoprotein C-III inhibitors such as Ionis’ olezarsen and Arrowhead’s plozasiran, as well as ANGPTL3-targeting therapies such as Eli Lilly’s solbinsiran.”

The trial enrolled 235 adults with elevated TG and remnant cholesterol levels. MAR001 achieved placebo-adjusted TG reductions of up to 45.5% at week 12, increasing to 57.2% among patients with higher baseline TG levels (≥300mg/dL). Remnant cholesterol was also reduced by up to 40.8%. However, MAR001 was associated with a modest increase in low-density lipoprotein cholesterol (LDL-C). Although the drug was generally well tolerated, previous preclinical concerns around lipid accumulation and inflammation in lymph nodes highlight the need for longer-term safety monitoring. A further Phase IIb trial in severe hypertriglyceridemia is underway.

Alexandrovich continues: “MAR001’s ability to lower both TGs and remnant cholesterol could make it an attractive option for patients with persistent lipid abnormalities despite existing treatment. However, the observed LDL-C increase may complicate its positioning for cardiovascular risk reduction, and longer-term safety data and evidence of clinical benefits will be important for broader uptake.”

Alexandrovich concludes: “TYDAL-TIMI 78 provides encouraging proof of concept for ANGPTL4 inhibition in dyslipidemia. Further positive results could strengthen MAR001’s commercial prospects and Marea Therapeutics’ appeal as a potential partner for larger pharmaceutical companies, although its place in the competitive TG-lowering market remains to be established.”